<DOC>
	<DOC>NCT01410370</DOC>
	<brief_summary>The aim of this study is to evaluate the clinical efficacy and safety of continuous Endostar infusion combined with radiotherapy for treatment of brain metastases.</brief_summary>
	<brief_title>Continuous Endostar Infusion Combined With Radiotherapy in Patients With Brain Metastases</brief_title>
	<detailed_description />
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Neoplasms, Second Primary</mesh_term>
	<mesh_term>Brain Neoplasms</mesh_term>
	<criteria>Histologically confirmed malignancy with presence of intraparenchymal brain metastases Karnofsky performance status ≥ 40 Measurable disease according to RECIST criteria Hematologic function: WBC ≥ 4.0×109/L, PLT ≥ 80×109/L, Hb ≥ 90g/L Renal function: Cr ≤ 2.0×ULN Hepatic function: BIL ≤ 2.0×ULN, ALT/AST ≤ 5.0×ULN Adequate cardiac function Life expectancy ≥ 3 months Evidence of bleeding diathesis or serious infection Serious cardiovascular disease (congestive heart failure, uncontrollable arrhythmia, unstable angina, myocardial infarction, serious heart valve disease, resistant hypertension) Uncontrollable mental and nervous disorders Pregnant or lactating women</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>Endostar</keyword>
	<keyword>Radiotherapy</keyword>
	<keyword>Brain Metastases</keyword>
</DOC>